The document doesn't seem to mention COVID or ARDS.
Source PDF is here: https://www.bluecrossmn.com/sites/default/files/DAM/2020-07/Final%20Medical%20and%20BH%20Policy%20Updates%20Bulletin%20P47-20.pdf
Looking up the other two therapies:
The FDA rejected the BLA for abicipar pegol in June 2020 due to an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration.
The FDA accepted the NDA for Bristol-Myers Squibb/Juno/Therapeutics Celgene’s lisocabtagene maraleucel for the treatment of large B-cell lymphoma and set a PDUFA date for August 2020. The PDUFA date was then delayed by three months in May 2020 to allow the FDA time to review new requested data for the drug. The new PDUFA date is 11/16/2020.
Source: https://www.prescriberight.com/pipeline-news
It could be that they're for different treatments and the policy is advanced preparation to use any of those for different conditions, as needed.
The document doesn't seem to mention COVID or ARDS.Source PDF is...
-
- There are more pages in this discussion • 146 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |